Semaglutide vs Retatrutide: UAE Research Comparison 2026
TL;DR. Semaglutide is a single GLP-1 agonist (Ozempic, Wegovy) — approved, well-established, ~15% weight loss at 68 weeks. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) — in phase 3, not approved, ~24% weight loss at 48 weeks (phase 2). Retatrutide is faster and deeper but the long-term safety dataset is years behind semaglutide.
The Two Generations
Semaglutide is the second-generation GLP-1 agonist (after liraglutide). It targets one receptor: GLP-1. Retatrutide is the next leap — a triple agonist that hits GLP-1, GIP, and glucagon receptors simultaneously. The pharmacological generations:
| Generation | Example | Receptors | Weight loss |
|---|---|---|---|
| 1st | Exenatide, liraglutide | GLP-1 | ~5–8% |
| 2nd | Semaglutide | GLP-1 | ~15% |
| 3rd | Tirzepatide (Mounjaro) | GLP-1, GIP | ~21% |
| 4th | Retatrutide | GLP-1, GIP, glucagon | ~24% (phase 2) |
Trial Data Head-to-Head
Semaglutide — STEP-1 (Wilding 2021, NEJM)
- 1,961 adults, BMI ≥30 or ≥27 with comorbidity
- 68 weeks treatment
- Dose: 2.4 mg weekly SC (Wegovy dose)
- Weight change: −14.9% vs −2.4% placebo
- ~70% achieved ≥10% weight loss; ~50% achieved ≥15%
Retatrutide — Jastreboff 2023 phase 2 (NEJM)
- 338 adults, BMI ≥30 without diabetes
- 48 weeks treatment
- Doses: 1, 4, 8, 12 mg weekly SC
- Weight change at 12 mg: −24.2% vs −2.1% placebo
- Plateau not yet reached at week 48 — curve still descending
Why Retatrutide Goes Deeper
Three pharmacological reasons retatrutide outperforms semaglutide on weight loss:
- GIP agonism amplifies satiety. GIP works synergistically with GLP-1 in the hypothalamus, reducing food intake beyond what GLP-1 alone can achieve.
- Glucagon agonism raises energy expenditure. Basal metabolic rate increases modestly — meaning weight loss isn't purely intake-driven but also output-driven.
- Hepatic fat targeting. The glucagon component preferentially mobilises liver fat, an effect semaglutide produces only secondarily through total weight loss.
Side Effects — Similar GI Profile, Different Cardiac
| Side effect | Semaglutide | Retatrutide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Less common | Less common |
| Diarrhoea | Common | Common |
| Constipation | Common | Common |
| Heart rate rise | Mild (+2 bpm) | Moderate (+6–8 bpm) |
| Gallbladder events | Slight increase | Slight increase |
| Hypoglycaemia (non-diabetic) | Rare | Rare |
The heart rate elevation with retatrutide is the most-watched difference — attributed to glucagon agonism. Phase 2 data showed no clinical cardiac events but phase 3 long-term cardiac monitoring is ongoing.
Dosing Comparison
REVIVE LAB UAE does not publish dosing, titration or administration schedules. The published trial literature cited on this page is the appropriate reference for study design.
REVIVE LAB UAE does not publish dosing, titration or administration schedules. The published trial literature cited on this page is the appropriate reference for study design.
See for syringe calculations.
UAE Availability and Cost
| Property | Semaglutide | Retatrutide |
|---|---|---|
| UAE pharmacy availability | Yes (Ozempic, Wegovy) | No (research only) |
| Prescription required | Yes | N/A |
| Approximate monthly cost (pharmacy) | AED 1,000–1,800 | N/A |
| Research peptide cost (per mg) | Comparable | Lower per mg |
Decision Framework
- If you need approved, prescribable weight loss treatment: semaglutide is the clear path. Approved, established, longest safety record.
- If you're running peptide research and want maximum weight-loss data: retatrutide has phase 2 effect sizes 50%+ larger than semaglutide.
- If safety record matters most: semaglutide has years more human data.
- If hepatic fat is the research target: retatrutide hits it directly via glucagon agonism.
Researching retatrutide in the UAE?
REVIVE supplies retatrutide 5 mg and 10 mg vials with HPLC certificates and cold-chain delivery.
View retatrutide vials →
REVIVE supplies retatrutide 5 mg and 10 mg vials with HPLC certificates and cold-chain delivery.
View retatrutide vials →
Order research peptides in the UAE
HPLC-verified vials · Same-day Dubai dispatch · Cash on delivery · 24h nationwide.
Browse Catalog ›
Research Desk
Research use only. Retatrutide supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption. Semaglutide (Ozempic, Wegovy) is a prescription medicine requiring medical supervision under UAE regulations. This page is informational and is not a recommendation. Any question that touches human health belongs with a qualified physician — nothing here replaces individual medical supervision.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971–984.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234–1247.